Clinical Trial Update: Plasma-Adapted First-Line Pembro In NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial update on plasma-adapted pembrolizumab as first-line therapy for non-small cell lung cancer; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Julia K. Rotow, MD | Conditions: NSCLC Stage IV, Metastatic Non-Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING